SLAMF1 and ovarian carcinoma: MeV oncolytic therapy is being tested in combination with other therapies, such as chemotherapy for peritoneal or ovarian cancer [19,24].The interactions of MeVs with host cells are mediated by three receptors, namely, Nectin-4, CD46, and SLAM/CD150.